EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Baseline patient demographics for TETRIS: a prospective, noninterventional study to characterize the use of triple therapy for COPD in Germany

Claus F Vogelmeier, Kai-Michael Beeh iD, Peter Kardos, Thomas Paulsson, Gernot Rohde, Henrik Watz, Chris Compton, Tharishini Mohan, Jing Claussen iD

Therapeutic Advances in Respiratory Disease · 2024

DOI: 10.1177/17534666241287621 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2024. Verfasst von Claus F Vogelmeier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Pulmonary and Critical Care Medicine, University of Marburg, German Center for Lung Research (DZL), Marburg, Germany. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Bronchodilator Agents, Drug Therapy, Combination. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence on how decisions regarding escalation to triple therapy and de- or re-escalation are taken and the rationale on which these decisions are based is currently limited in Germany.

Objectives

The TETRIS study aims to elucidate influences on treatment decisions surrounding triple therapy in a real-world practice setting in Germany.

Design

TETRIS is an ongoing, multicenter, prospective, observational cohort study recruiting patients with chronic obstructive pulmonary disease (COPD) with or without asthma who have already been treated with triple therapy for 2–48 weeks.

Methods

For better representation of the treatment reality in Germany, patients are recruited from general practitioners and pulmonologists. Data are collected in two parts. Part 1 involves cross-sectional phenotyping of patients at enrollment. Part 2 involves a 2-year longitudinal follow-up period to monitor/document all visits by the patients during the 24-month observation period per routine clinical practice. Here, we report the demographic and baseline characteristics of 1213 eligible patients recruited to part 1 of the study.

Results

The mean patient age was 66.4 years overall, and 29.3% (356/1213) of patients had no comorbidities. The mean CAT score was 19.4; the number of exacerbations and hospitalizations due to exacerbations in the past 3 years before starting triple therapy was 0.6 and 0.1, respectively. Dual bronchodilation with a long-acting muscarinic antagonist (LAMA) plus a long-acting β-2 agonist (LABA) was the most common therapy for COPD before initiation of triple therapy in 58.3% of patients.

Conclusion

In this real-world setting in Germany, patients with COPD have a relatively low reported exacerbation rate but high symptom burden, and over 70% are multimorbid. Triple therapy is initiated in patients who are primarily highly symptomatic despite being on LAMA + LABA. Future prospective studies in patients with multimorbidity are warranted to better understand the treatment landscape across the disease spectrum. Trial registration: https://clinicaltrials.gov/study/NCT04657211

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveBronchodilator AgentsDrug Therapy, CombinationHumansMaleFemaleGermanyProspective StudiesAgedMiddle AgedTreatment OutcomeCross-Sectional StudiesAdrenergic beta-2 Receptor AgonistsMuscarinic AntagonistsTime FactorsLongitudinal StudiesLungDisease ProgressionClinical Decision-MakingPractice Patterns, Physicians'

Stichwörter der Autor:innen

blood eosinophil countchronic obstructive pulmonary diseaseexacerbationmultiple-inhaler triple therapysingle-inhaler triple therapyspirometrytriple therapy

Substanzen

Bronchodilator AgentsAdrenergic beta-2 Receptor AgonistsMuscarinic Antagonists

Autor:innen und Institutionen

  • Department of Medicine, Pulmonary and Critical Care Medicine, University of Marburg, German Center for Lung Research (DZL), Marburg, Germany.
  • Insaf Respiratory Research Institute, GmbH, Taunusstein, Germany.
  • Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, Frankfurt am Main, Germany.
  • GSK, Brentford, Middlesex, UK.
  • Goethe University Frankfurt, University Hospital, Medical Clinic I, Department of Respiratory Medicine, Frankfurt/Main, Germany.
  • Velocity Clinical Research Grosshansdorf, formerly Pulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany.

ORCID-Profile: Kai-Michael Beeh, Jing Claussen

Förderung

  • GSK

Zitieren

APA

Vogelmeier, C. F., Beeh, K. M., Kardos, P., Paulsson, T., Rohde, G., Watz, H., Compton, C., Mohan, T., & Claussen, J. (2024). Baseline patient demographics for TETRIS: a prospective, noninterventional study to characterize the use of triple therapy for COPD in Germany. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666241287621

Vancouver

Vogelmeier CF, Beeh KM, Kardos P, Paulsson T, Rohde G, Watz H, et al. Baseline patient demographics for TETRIS: a prospective, noninterventional study to characterize the use of triple therapy for COPD in Germany. Therapeutic Advances in Respiratory Disease. 2024. doi:10.1177/17534666241287621

BibTeX
@article{Vogelmeier2024,
  author = {Vogelmeier, Claus F and Beeh, Kai-Michael and Kardos, Peter and Paulsson, Thomas and Rohde, Gernot and Watz, Henrik and Compton, Chris and Mohan, Tharishini and Claussen, Jing},
  title = {Baseline patient demographics for TETRIS: a prospective, noninterventional study to characterize the use of triple therapy for COPD in Germany},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2024},
  doi = {10.1177/17534666241287621}
}
Kostenlos starten →